We are pleased to announce that Wren Laboratories will sponsor the NANETS Regional Conference series this year, including the first one in Miami this Saturday, April 6th. A series of regional NET Education programs offered in conjunction with local cancer centers to provide multidisciplinary training to medical professionals across North America, these conferences bring oncologists, physicians, researchers and allied Nanets Logohealthcare providers together with leaders in neuroendocrine medicine to educate and discuss NET disease and patient care in the community and across the U.S.

As a company that has focused on neuroendocrine cancer since our founding almost a decade ago, having the opportunity to enable the exchange of knowledge about this rare disease is very fulfilling for us. This is because knowledge is critical to helping neuroendocrine cancer patients. Research shows that by the time most NET patients are diagnosed, their disease has been active for almost 4 and a half years. Any forum where knowledge about NETs can help raise awareness.

We will have a booth at these NANETS Regional events where conference participants can learnWren Booth at NANETS more about our mRNA-based neuroendocrine cancer diagnostic, the NETest as well as our Peptide Receptor Radionuclide Therapy response predictor, the PPQ. Please stop by with questions or to get more information. If you can’t make the conference, following is a director of the peer-reviewed papers we will have on hand for your perusal:

NETest Accuracy: A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.

PPQ PRRT Response: Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumors.

Post Resection: Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy.

Chromogranin A Comparison: NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis.

Clinical Utility: NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon.

If you would like to learn more about our two Neuroendocrine Cancer diagnostics, please contact us.